News

The filing for Keppra is supported by a Phase III, multicenter, randomized, double-blind, placebo-controlled study evaluating the efficacy, safety, and tolerability of extended-release levetiracetam tablets (2x500mg) once-daily as

This multi-center Phase III trial will include a randomized, double blind, placebo-controlled component to evaluate the efficacy and safety of MAP0004 in treating a single acute attack of

Approval from the FDA to proceed with the pivotal phase of the study is based on the review of an initial feasibility segment completed in August 2007. The

During the 48-week study, the standard Psoriasis Area and Severity Index (PASI 75) was used to evaluate the efficacy of Enbrel in patients between 4 and 17 years

The crossover study (CG106) will characterize the pharmacodynamic effects of CGT-2168 compared with Plavix and will expand earlier findings of comparability. Separately, Cogentus has begun Cogent-1, a global

Rhei Pharmaceuticals will be responsible for marketing MuGard in China, Hong Kong, Macau, Taiwan, Brunei, Cambodia, Indonesia, Laos, Malaysia, Myanmar, Philippines, Singapore, Thailand and Vietnam, as well as

One of the studies, designated the ‘SUPPORT’ study, will assess the efficacy and safety of Cerimon’s patch compared to placebo for the treatment of pain due to acute

Under this agreement, Pfizer will obtain a worldwide exclusive license to develop and commercialize CD-RAP. In addition to receiving royalties on the sale of any products that may

The decision of the FDA allows the product to be sold in the US, where it is patent protected until 2017. Nycomed is in active negotiations with possible